troglitazone has been researched along with Endometrial Neoplasms in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Surazynski, A | 1 |
| Jarzabek, K | 1 |
| Miltyk, W | 1 |
| Wolczynski, S | 1 |
| Palka, J | 1 |
1 other study available for troglitazone and Endometrial Neoplasms
| Article | Year |
|---|---|
Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromans; Collagen; Endometrial Neoplasms; Estrogens; Female; Huma | 2009 |